Agile Therapeutics, Inc. (NASDAQ:AGRX) has been assigned a $8.00 price target by equities researchers at Royal Bank Of Canada in a research note issued to investors on Sunday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 91.39% from the company’s previous close.

A number of other equities analysts have also issued reports on AGRX. Cantor Fitzgerald increased their target price on shares of Agile Therapeutics from $7.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, April 4th. ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, June 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $9.92.

Shares of Agile Therapeutics (NASDAQ AGRX) traded up 5.03% during mid-day trading on Friday, hitting $4.18. 70,014 shares of the company traded hands. The firm’s market cap is $120.41 million. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.15. The firm has a 50-day moving average price of $3.65 and a 200 day moving average price of $3.34.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/07/16/agile-therapeutics-inc-nasdaqagrx-receives-buy-rating-from-royal-bank-of-canada.html.

In other Agile Therapeutics news, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was bought at an average cost of $3.51 per share, with a total value of $35,100.00. Following the acquisition, the chairman now owns 151,587 shares of the company’s stock, valued at $532,070.37. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Renee Selman purchased 53,333 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was acquired at an average cost of $3.68 per share, with a total value of $196,265.44. Following the completion of the acquisition, the insider now directly owns 53,333 shares in the company, valued at approximately $196,265.44. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Agile Therapeutics stock. Royce & Associates LP raised its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 206.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 987,582 shares of the specialty pharmaceutical company’s stock after buying an additional 665,000 shares during the period. Royce & Associates LP’s holdings in Agile Therapeutics were worth $3,165,000 as of its most recent filing with the SEC. 79.78% of the stock is currently owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.